Financials argenx SE

Equities

ARGX

NL0010832176

Biotechnology & Medical Research

Real-time Euronext Bruxelles 10:06:35 2024-05-13 am EDT 5-day change 1st Jan Change
346.1 EUR -0.52% Intraday chart for argenx SE -3.46% +0.79%

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 6,141 11,400 16,291 19,269 20,293 20,661 - -
Enterprise Value (EV) 1 4,811 9,781 14,186 18,515 17,352 18,299 18,172 17,672
P/E ratio -34 x -20.8 x -43.8 x -28.3 x -72.1 x -133 x 106 x 34.3 x
Yield - - - - - - - -
Capitalization / Revenue 74.4 x 209 x 33.5 x 45.9 x 17.3 x 12 x 9.04 x 7.08 x
EV / Revenue 58.3 x 179 x 29.2 x 44.1 x 14.8 x 10.7 x 7.96 x 6.06 x
EV / EBITDA -27.3 x -23.6 x -45.7 x -31.9 x -59.8 x -73.2 x 75.5 x 23.2 x
EV / FCF 36.2 x -28.2 x -25.7 x -22.8 x -40.4 x -74.9 x 139 x 41.6 x
FCF Yield 2.76% -3.55% -3.9% -4.39% -2.47% -1.33% 0.72% 2.4%
Price to Book 5.84 x 8.44 x 7.1 x - 5.39 x 5.48 x 5.1 x 4.39 x
Nbr of stocks (in thousands) 42,762 47,108 51,668 55,324 59,079 59,387 - -
Reference price 2 143.6 242.0 315.3 348.3 343.5 347.9 347.9 347.9
Announcement Date 2/27/20 3/4/21 3/3/22 3/2/23 2/29/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 82.58 54.53 486.3 419.9 1,171 1,715 2,284 2,916
EBITDA 1 -176.4 -414.3 -310.4 -580.3 -290.2 -250 240.6 762
EBIT 1 -178.6 -417.8 -314.4 -679.3 -392.3 -250.8 108.9 640.9
Operating Margin -216.21% -766.07% -64.65% -161.78% -33.51% -14.63% 4.77% 21.98%
Earnings before Tax (EBT) 1 -158.2 -526.3 -360.4 -687.7 -281 -151.6 192.9 696.6
Net income 1 -163 -528.9 -368.1 -669.1 -272.3 -163.4 169.2 632.3
Net margin -197.33% -969.9% -75.69% -159.36% -23.26% -9.53% 7.41% 21.68%
EPS 2 -4.220 -11.65 -7.203 -12.31 -4.763 -2.622 3.284 10.14
Free Cash Flow 1 133 -347.3 -552.7 -813.6 -429.4 -244.2 130.8 424.4
FCF margin 161.02% -636.85% -113.66% -193.76% -36.67% -14.24% 5.73% 14.55%
FCF Conversion (EBITDA) - - - - - - 54.38% 55.7%
FCF Conversion (Net income) - - - - - - 77.35% 67.12%
Dividend per Share 2 - - - - - - - -
Announcement Date 2/27/20 3/4/21 3/3/22 3/2/23 2/29/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2019 S2 2021 Q3 2021 Q4 2021 S2 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2022 S2 2023 Q1 2023 Q2 2023 S1 2023 Q3 2023 Q4 2023 S2 2024 Q1 2024 Q2 2024 S1 2024 Q3 2024 Q4 2024 S2 2025 Q1
Net sales 1 31.28 6.131 40.42 - 29.8 84.08 145.5 171.7 309.9 207.8 253.8 461.4 320.3 385.7 699.3 383.8 403.9 783 439 480.3 887.9 500.7
EBITDA 1 - -182.1 -197.7 - -211.5 -170.3 -208 - - - - - - - - -70.62 -93.13 - -99 -61.53 - -
EBIT 1 -94.09 -183.8 -208.2 - -210.9 -172.3 -207.2 -107.9 -304.7 -93.84 -92.2 -185.9 -75.95 -127.9 -202.3 -86.93 -77.7 -169.8 -60.6 -36.2 -151.2 11.42
Operating Margin -300.74% -2,997.28% -515.01% - -707.52% -204.9% -142.43% -62.83% -98.32% -45.15% -36.33% -40.29% -23.71% -33.18% -28.93% -22.65% -19.23% -21.69% -13.8% -7.54% -17.03% 2.28%
Earnings before Tax (EBT) 1 -113.4 -199.2 -220.8 - -217.8 -214.2 -239.4 -38.89 -266.2 -68.9 -75.73 -144.5 -78.49 -56.47 -133.3 -69.18 -48.24 -64.05 -29.64 -11.23 -60.64 20.45
Net income 1 -117.8 -201.6 -214.4 -425 -215.1 -206 -233.5 -36.41 -258.1 -26.11 -85.22 -111.3 -68.47 -91.54 -158.6 -57.32 -51.32 -64.05 -32.32 -15.72 -60.64 26.93
Net margin -376.68% -3,288.02% -530.42% - -721.69% -245.06% -160.45% -21.2% -83.28% -12.57% -33.58% -24.12% -21.38% -23.73% -22.68% -14.93% -12.7% -8.18% -7.36% -3.27% -6.83% 5.38%
EPS 2 - -3.797 -4.291 - - -3.760 -4.231 -0.6601 - -0.4703 -1.526 - -1.178 -1.551 - -0.5995 -1.246 - -1.360 -0.4450 - -
Dividend per Share 2 - - - - - - - - - - - - - - - - - - - - - -
Announcement Date 2/27/20 10/28/21 3/3/22 3/3/22 5/5/22 7/28/22 10/27/22 3/2/23 3/2/23 5/4/23 7/27/23 7/27/23 10/31/23 2/29/24 2/29/24 5/9/24 - - - - - -
1EUR in Million2EUR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 1,329 1,619 2,105 754 2,942 2,362 2,488 2,988
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 133 -347 -553 -814 -429 -244 131 424
ROE (net income / shareholders' equity) -20.5% -43.8% -19.4% -26.5% -8.54% -5.6% 4.45% 16%
ROA (Net income/ Total Assets) -16.2% -32.1% -15.9% -23.7% -7.69% -2.85% 4.89% 13.8%
Assets 1 1,006 1,646 2,312 2,822 3,543 5,740 3,457 4,586
Book Value Per Share 2 24.60 28.70 44.40 - 63.70 63.50 68.20 79.30
Cash Flow per Share 2 - - -10.80 - -6.800 1.570 3.090 10.70
Capex 1 1.6 0.95 3.28 0.79 - 12.2 12.8 18.2
Capex / Sales 1.94% 1.74% 0.67% 0.19% - 0.71% 0.56% 0.62%
Announcement Date 2/27/20 3/4/21 3/3/22 3/2/23 2/29/24 - - -
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
347.9 EUR
Average target price
435.1 EUR
Spread / Average Target
+25.07%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW